Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage II colorectal cancer

Oncology Reports

Volumn 20, Issue 5, 2008, Pages 1189-1194

  Ito, Isao ^a   Mukai, Masaya ^b   Ninomiya, Hiromi ^a   Kishima, Kyoko ^b   Tsuchiya, Kazutoshi ^a   Tajima, Takayuki ^b   Oida, Yasuhisa ^c   Nakamura, Masato ^b   Makuuchi, Hiroyasu ^c  

^a TOKAI UNIVERSITY OISO HOSPITAL   (Japan)

^b TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 FU LV; Adjuvant chemotherapy; Colorectal cancer; Isolated tumor cells; Occult neoplastic cells; PSK (Krestin); UFT

Indexed keywords

FLUOROURACIL; FOLINIC ACID; KRESTIN; UFT; ANTINEOPLASTIC AGENT;

ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PIGMENTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; TASTE DISORDER; THROMBOCYTOPENIA; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; LEUCOVORIN; NEOPLASM STAGING; QUALITY OF LIFE; RETROSPECTIVE STUDIES;

EID: 58149329043     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000128     Document Type: Article

References (34)

1. Japanese Society for Cancer of the Colon and Rectum: Multi-Institutional Registry of Large Bowel Cancer in Japan, Vol. 23, Cases treated in 1994. Kanehara & Co., Ltd., Tokyo, 2002.
2. Knacks & Pitfalls: Surgery of the Colon, Rectum and Anus. 2nd edition. Bunkoudou & Co., Ltd., Tokyo, 2004.
3. Japanese Society for Cancer of the Colon and Rectum: Guideline for Large Bowel Cancer in Japan. Kanehara & Co., Ltd., Tokyo, 2005.
4. Mukai M, Ito I, Mukoyama S, Tajima T, Saito Y, Nakasaki H, Sato S and Makuuchi H: Improvement of 10-year survival by Japanese radical lymph node dissection in patients with Dukes' B and C colorectal cancer: A 17-year retrospective study. Oncol Rep 10: 927-934, 2003.
5. Mukai M, Sato S, Komatsu N, Nishida T, Shiba K, Ito I, Nakasaki H and Makuuchi H: Correlation between occult neoplastic cells in the lymph node sinuses and recurrence in patients with Dukes' C colorectal cancer. Oncol Rep 10: 1165-1169, 2003.
6. Mukai M, Sato S, Komatsu N, Nishida T, Shiba K, Ito I, Nakasaki H and Makuuchi H: Correlation between occult neoplastic cells in the lymph node sinuses and recurrence in patients with curatively resected Dukes' B colorectal cancer. Oncol Rep 10: 1177-1181, 2003.
7. Mukai M, Sato S, Nakasaki H, Saito Y, Nishiumi N, Iwasaki M, Tokuda Y, Ogoshi K, Inoue H and Makuuchi H: Occult neoplastic cells in the lymph node sinuses and recurrence of primary breast, lung, esophageal and gastric cancer. Oncol Rep 11: 81-84, 2004.
8. Mukai M, Sato S, Komatsu N, Kimura T, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi M: Accuracy of criteria for predicting the recurrence and metastasis of stage I and II gastric cancer without lymph node metastasis. Oncol Rep 12: 59-62, 2004.
9. Mukai M, Sato S, Komatsu N, Kimura T, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Accuracy of criteria for predicting recurrence and metastasis in stage II and III gastric cancer with lymph node metastasis. Oncol Rep 12: 63-66, 2004.
10. Mukai M, Sato S, Komatsu N, Kimura T, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Predicting the recurrence/metastasis of stage II and III breast cancer with lymph node metastasis. Oncol Rep 12: 303-306, 2004.
11. Mukai M, Sato S, Komatsu N, Kimura T, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Predicting the recurrence/metastasis of stage I and II breast cancer without lymph node metastasis. Oncol Rep 12: 745-748, 2004.
12. Mukai M, Sato S, Nishida T, Komatsu N, Shiba K, Nakasaki H, and Makuuchi H: Selection criteria for high risk and low risk groups of recurrence and metastasis in patients with primary colorectal cancer. Oncol Rep 10: 1753-1758, 2003.
13. TNM Classification of Malignant Tumours. 6th edition, John Wiley & Sons, Inc., New York, 2002.
14. Mukai M: Occult neoplastic cells and malignant micro-aggregates in lymph node sinuses: Review and hypothesis. Oncol Rep 14: 173-175, 2005.
15. Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tsuchiya K, Tajima T, Nakasaki H and Makuuchi H: Prospective study on the recurrence/ metastasis of stage II/III colorectal and gastric cancer associated with occult neoplastic cells in lymph node sinuses: Three-year interim results. Oncol Rep 16: 405-410, 2006.
16. Mukai M, Oida Y, Tajima T, Kishima K, Ninomiya H, Sato S, Nakamura M, Nakasaki H and Makuuchi H: Alternating hepatic arterial infusion and systemic chemotherapy for stage IV colorectal cancer with synchronous liver metastasis. Oncol Rep 16: 865-870, 2006.
17. Mukai M, Moriya H, Himeno S, Oida Y, Mukoyama S, Nishi T, Nakasaki H, Sato S and Makuuchi H: Efficacy of oral UFT plus leucovorin therapy for colon cancer with ovarian and multiple liver metastases: Report of two cases. Oncol Rep 8: 1079-1083, 2001.
18. Wolmark N, Wieand S, Lembersky B, Colangelo L, Smith R and Pazdur R: A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP protocol C-06. Proc Am Soc Clin Oncol 22 (14S): 247s, #358, 2004.
19. Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G and Wolmark N: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24: 2059-64, 2006.
20. Mukai M, Tajima T, Nakasaki H, Sato S, Ogoshi K and Makuuchi H: Efficacy of postoperative adjuvant oral immunochemotherapy in patients with Dukes' B colorectal cancer. Ann Cancer Res Therap 11: 201-214, 2003.
21. Mukai M, Tajima T, Nakasaki H, Sato S, Ogoshi K and Makuuchi H: Efficacy of postoperative adjuvant oral immunochemotherapy in patients with Dukes' C colorectal cancer. Ann Cancer Res Therap 11: 215-229, 2003.
22. Mukai M, Tokunaga N, Yasuda S, Mukoyama S, Itoh I, Kameya T, Ishikawa K, Iwase H, Suzuki T, Ishida H, Sadahiro S and Makukuchi H: Long-term survival after immunochemotherapy in a patient of juvenile colon cancer with peritoneal dissemination: A case report. Oncol Rep 7: 1343-1347, 2000.
23. Mitomi T, Tsuchiya S, Iijima N, Aso K, Suzuki K, Nishiyama K, Amano T, Takahashi T, Murayama N, Oka H, Oya K, Noto T and Ogawa N: Randomized controlled study on adjuvant immnochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of the Colon and Rectum (Kanagawa). Dis Colon Rectum 35: 123-130, 1992.
24. Nakazato H, Koike A, Saji S, Ogawa N and Sakamoto J: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 33: 1122-1126, 1994.
25. Sakamoto J, Hamada C, Kodaira S, Nakazato H and Ohashi Y: Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials. Jpn J Clin Oncol 29: 78-86, 1999.
26. Munemoto Y, Iida Y, Abe J, Saito H, Fujisawa K, Kasahara Y, Mitsui T, Asada Y and Miura S: Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: Association between host or tumor factors and survival. Int J Oncol 20: 403-411, 2002.
27. Koda K, Miyazaki M, Sarashina H, Suwa T, Saito N, Suzuki M, Ogawa K, Watanabe S, Kodaira S and Nakazato H: A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. Int J Oncol 23: 165-172, 2003.
28. Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwazaki S, Ishikawa H, Kawate S, Nakajima T and Morishita Y: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer. Br J Cancer 90: 1003-1010, 2004.
29. Sakamoto J, Morita J, Oba K, Matsui T, Kobayashi M, Nakazato H and Ohashi Y: Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: A meta-anlysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 55: 404-411, 2006.
30. Machover D, Schwarzenberg L, Goldschmidt E, Tourani JM, Michalski B, Hayat M, Dorval T, Misset JL, Jasmin C, Maral R and Mathe G: Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study. Cancer Treat Rep 66: 1803-1807, 1982.
31. General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus. Japanese Society for Cancer of the Colon and Rectum. 7th edition, Kanehara & Co., Ltd., Tokyo, 2006.
32. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller L, for the Irinotecan study group: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914, 2000.
33. Tournigand C, Achille TAE, Lledo G, Flesh M, Quinaux DM-ME, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and De Gramont A: FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
34. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Carten G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Seri MD, Lopez M and Maiello E: Phase III randomized trial of FOLFIRI versus FOLFOX 4 in the treatment of advanced colorectal cancer: A multicenter study of Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23: 4866-4875, 2005.